# The Journal of the Intellectual Property Office of New Zealand

Journal Number 1737 Published on 22 March 2024 ISSN 2422-9652

## Days on which the Intellectual Property Office is Closed

In accordance with section 223 of the Patents Act 2013, section 188 (1) of the Trade Marks Act 2002 and section 45(1) of the Designs Act 1953, the Intellectual Property Office of New Zealand is open every-day except the following Official closed days:

- a. All Saturdays and Sundays
- b. Wellington Anniversary Day
- c. The holiday observed as Waitangi Day
- d. Good Friday and Easter Monday
- e. The holiday observed as ANZAC Day
- f. The holiday observed as the Sovereign's birthday
- g. Te Rā Aro ki a Matariki/Matariki Observance Day
- h. Labour Day
- i. Christmas Day, to and including:
- the 2nd day of January in any year when New Year's Day falls on a Monday, Tuesday, Wednesday or Thursday or
- the 3rd day of January in any year when New Year's Day falls on a Sunday or
- the 4th day of January in any year when New Year's Day falls on a Friday or Saturday

The Intellectual Property Office of New Zealand physical office is open for business 8.30am – 5.00pm NZDST.

Applications and documents for Patents, Trade Marks or Designs that are submitted online on an open day will receive that day as a filing date if they are submitted no later than 11.59pm NZDST.

Applications and documents submitted online on a day when the Office is closed will receive the date of the next open day as the official filing date regardless of the date of submission.

If the deadline for filing an application or document falls on a day when the Office is closed, then the application or document will be filed on the next open day.

#### Please note:

As a general rule, if the details of an invention or design, for which an application for a patent or design registration is to be made, are published prior to the official filing date, it may invalidate the patent or registration. Therefore, if a patent or design application is submitted online on an official closed day, the details of the invention or design should not be publicly disclosed until after the official filing date which will be later than the date of online submission.

It is mandatory to use the <u>online case management facility</u> when communicating with IPONZ about International and New Zealand Trade Marks and Patents filed under the Patents Act 2013. Communications received outside the case management facility will not be considered valid unless exceptional circumstances exist.

Dated this 2 February 2017

Ross van der Schyff Commissioner of Patents Commissioner of Trade Marks Commissioner of Designs

#### Information Section

General Information Section1
Expected Publication Dates1
PONZ Fee Schedule2
Trade Marks
Designs
Patents Act 1953
Patents Act 2013 and Patent Regulations 2014 - Schedule
Fees and Penalties
Patent Cooperation Treaty System (PCT)3
PCT Fees
Section 85 Amendment of Specification 4

#### **General Information Section**

The Journal of the Intellectual Property Office of New Zealand contains information the Commissioner is required by the Patents Act 2013 to advertise. It is published on a monthly basis and consists of a General Information section in pdf format, and an online section for case specific information. This document is the General Information section. To view the case specific information of the Journal see <a href="https://example.com/html/>
The Journal">The Journal</a> > <a href="https://example.com/html/>
Our journal facility.

#### **Expected Publication Dates**

Journal No.	Publication Date
1738	26 April 2024
1739	31 May 2024

#### IPONZ Fee Schedule

#### **Trade Marks**

Fee	(excl. Fee GST)	(incl.GST)	
Search/Advice			
Request for combine Search and prel	liminary		
(per class)	\$50.00	\$57.50	
Request for Search (per class) - this will also include a preliminary ac	\$50.00 dvice report	\$57.50	
Request for Preliminary Advice (per c - this will also include a search report.	•	\$57.50	
Annillandian			
Application Application for Trade Mark (per class)		\$115.00	
Where the specification consists onl tions for that class, and relevant se advice was not obtained (or neither	earch advice or er was obtained	preliminary	
months before the application was ma	\$70.00	\$80.50	
Where both the search advice and preliminary advice obtained within 3 months before the application was made, and the information contained in the application is the same as the information.			
mation to which the advice relates (per class)	\$50.00	\$57.50	
Application for additional class(es) (pe	er class) \$100.00	\$115.00	
Renewals			
Renewal of all trade marks including	g series marks \$200.00	(per class) \$230.00	
Oppositions/Hearings			
Notices of Opposition by Opponent	\$350.00	\$402.50	
Hearing fee for each party	\$850.00	\$977.50	
Application for Revocation of Applicati	ion of		
Trade Mark	\$350.00	\$402.50	
Application for Declaration of Invalidity	y of		
Registration	\$350.00 ——	\$402.50	
Designs	;		
Fee Applications	(excl. Fee GST)	(incl.GST)	
Application to register one design to a	single article		
	\$100.00	\$115.00	
Application to register one design to a	a set of articles		
Renewals	\$100.00	\$115.00	
(2nd period of 5 years)	\$100.00	\$115.00	
(3rd period of 5 years)	\$200.00	\$230.00	
Oppositions/Hearings			
On all notices of opposition by oppor	nent \$300.00	\$345.00	
Hearing by Commissioner, for each p		\$862.50	
Copies	Ţ. <b>20.00</b>	,	
Copies of Certificates, certified copie ister	es or extracts from	m the Reg- FREE	

#### Patents Act 1953

Fee ——— (excl. Fee GST) (incl.GST)

#### **Application**

On filing complete specification under the Patents Act 1953

\$500.00 \$575.00

#### **Amendments**

Amend Complete Specification before a Act 1953	acceptance u \$150.00	nder Patents \$172.50
Amend Complete Specification after acc 1953	eptance unde \$500.00	r Patents Act \$575.00
Renewals		
4th year renewal	\$170.00	\$195.50
7th year renewal	\$340.00	\$391.00
10th year renewal	\$540.00	\$621.00
13th year renewal	\$1000.00	\$1150.00
Oppositions/Hearings		
On all notices of opposition by opponent	\$300.00	\$345.00
On hearing by Commissioner, for each party		
	\$750.00	\$862.50

#### Copies

 $35(1)^{1}$ 

 $35(1)^1$ 

tion 9(1)(a)

by regulation 9(1)(b)

Copies of Certificates, certified copies or extracts from the Register FREE

## Patents Act 2013 and Patent Regulations 2014 – Schedule Fees and Penalties

The fees and penalties schedule for all matters under the Patents Act 2013 and Patents Regulations 2014 is set out below.

#### Part 1

#### Matters under Act and regulations

Section of	Act	Fee	(excl. Fee GS	T) (incl.GST)
20(2)1			4th, 5th, 6th, 7th te of the comple \$200.00	,
20(2) <sup>1</sup>			10th, 11th, 12th, ite of the comple \$450.00	•
20(2) <sup>1</sup>			15th, 16th, 17th, te of the comple \$1000.00	•
21(2)(c)	Penalty pay ment of a re	•	st to extend the \$100.00	period for pay- \$115.00
32	Patent application	lication accom	panied by a pro \$100.00	visional specifi- \$115.00
		ion accompani ention applicati	ed by a complet ons) \$250.00	e specification \$287.50

Maintenance fee due on the 4th and each subsequent anniversary of the filing date of the complete specification if the fee is paid during the period prescribed by regula-

Maintenance fee due on the 4th and each subsequent anniversary of the filing date of the complete specification if the fee is paid during the further period prescribed

\$200.00

\$300.00

\$230.00

\$345.00

Section of Act Fee (ex		(excl. Fee GST)	(incl.GST)	
40	Amendment by applicant of complete specification before acceptance (other than in response to an objection raised in a report issued by the Commissioner under section 65 or 97 of the Act) \$150.00 \$172.50			
64, 94,95	Request for examination or re-examination \$750.00 \$862.50			
85(3)	Request for acceptance	leave to ame	end complete spe \$500.00	ecification after \$575.00
11A	Excess claims fee for examinations of patent application with 30 claims or more on any application for which request for examinations is made on or after 13 February 2020 (for each 5th claim over 25)  \$120.00 \$138.00			
125(2)	Request for	r restoration o	of patent or pate \$600.00	nt application \$690.00
87, 92, 1,16(3)				
123, 127 202(4)	Notice of op	position	\$350.00	\$402.50
112(1)	Application t	to revoke a pat	ent \$350.00	\$402.50
117(2), Various Request for a hearing \$850.00 \$977.50				\$977.50

### Part 2 Patent Cooperation Treaty

Legislative/Treaty Fee (excl. Fee GST) (incl.GST) basis

#### International phase

Rule 14.1

Treaty

Regulations Transmittal fee for each international application, payable to the Commissioner within 1 month of the applicant filing the international application

\$180.00 \$207.00

#### **National phase**

Section 46

of Act

Application for entry into the national phase of a Treaty application (treated as a patent application accompanied by a complete specification)

\$250.00 \$287.50

The Patents Act 1953, the Patents Regulations 1954 (including fees) orders, directions, and other matters made under it continue to apply, as if sections 247 to 249 of the Patents Act 2013 were not in force, for the purposes of:

- a patent application made under the Patents Act 1953 before the commencement of Part 3 of this Act; and
- the bringing and completion of any application, request, notice, or other proceeding relating to that application, whether commenced before or after the commencement of Part 3 of this Act.

#### Patent Cooperation Treaty System (PCT)

#### **PCT Fees**

The Patents Amendment Act 1992 (apart from sections 3, 8, and 11, which came into force on 19 August 1992) and the Patents (Patent Cooperation Treaty) Regulations 1992 came into force on 1 July 1998.

Please see the <u>PCT fee schedules on the WIPO website</u> for the most current information.

The Patent Cooperation Schedule of Fees has been amended with effect from 1 January 2024. The revised schedule of fees is as follows.

#### The International Phase:

#### New Zealand component

The transmittal fee for each international application:

NZD \$180.00 + \$27.00 (GST) = \$207.00

#### International component

The International fees, collected by the Intellectual Property Office of New Zealand on behalf of the International Bureau, are as follows ("Rule" refers to the Regulations under the Patent Cooperation Treaty):

Basic Fee: (Rule 15.2(a)):

International Filing Fee	NZD	\$2436.00
Fee per sheet over 30	NZD	\$27.00
e-PCT PDF Filing Reduction	NZD	\$366.00
e-PCT XML Filing Reduction	NZD	\$550.00

#### International Search Fee: (Rule 16.1(b)):

The Australian Patent Office, the European Patent Office and United States Patent Offices have been specified, pursuant to Articles 16(2) and 32(2) of the Patent Cooperation Treaty, as being competent for the searching and preliminary examination of international applications filed with the Intellectual Property Office of New Zealand. Only one search authority is to be selected. The search fees, collected by IP-ONZ on behalf of the requisite International Searching Authority, are as follows:

Australian Patent Office (AU)	NZD	\$2357.00
European Patent Office (EP)	NZD	\$3132.00
As of 01 Apr 2024	NZD	\$3253.00
Korean Intellectual Property Office (KR)	NZD	\$1473.00
United States Patent and Trade Mark Office (L	JS)	
•	NZD	\$3652.00
(US) small entity search	NZD	\$1461.00
(US) micro entity search	NZD	\$730.00
NOTE:		

- 1. The listed fees are exclusive of GST (except where stated).
- IPONZ require direct credit payments for PCT International applications. Once you have filed a PCT International application you will receive an email with the summary of the fees due. The email will also include MBIE PCT Trust Account details which you will need to direct credit your payment into.

#### **National Phase:**

On entry into the national phase of a Treaty application for a patent NZD \$250.00 + (\$37.50 GST where applicable)

Please use our online service (<u>www.iponz.govt.nz/manage-ip</u> > <u>Apply</u> <u>for a PCT national phase entry</u>) to file a National Phase application.

The Journal of the Intellectual Property Office 1737 22 March 2024

<sup>&</sup>lt;sup>1</sup> The period for payment of these fees commences three months <u>before</u> the anniversary of the filing date of the complete specification and ends at the close of the anniversary date.

#### Section 85 Amendment of Specification Nature of Amendment

An application for amendment of patent 598971, entitled, GRANULAT-ED COMPOSITIONS AND THEIR USE. The patentee (RDG TECH-NOLOGIES LIMITED) notes in their letter of 10 November 2023 that the wherein the granules are of a size or sizes in the range from 1 to amendments proposed are by way of disclaimer and/or explanation and/or correction.

IPONZ noted in their letter of 24 November 2023 that the provisions of s85(3)(a) were thus met despite some amendments being unallowable. The patentee then proposed further amendments in submissions of 7 February 2024 with no change proposed to "by way of disclaimer and/or explanation and/or correction:. IPONZ considers that s85(3)(a) remains met in this respect.

The patentee proposed amendments of 7 February 2024 in mark-up format based on the current complete specification are claims only as follows:

#### WHAT WE CLAIM IS:

- Dietary supplement granules suitable for animals, each 1. granule being a granulation of consistent mix ratio of at least three types of particle, the particles being
- (i) particles of at least one particulate source of calcium not in the zero oxidation state and in a nutritionally available form ("calcium particles"),
- (ii) particles of at least one particulate source of magnesium not in the zero oxidation state and in a nutritionally available form ("magnesium particles"), and
- (iii) particles of at least one particulate source of sodium not in the zero oxidation state and in a nutritionally available form ("sodium particles");

#### wherein

the calcium particles when expressed as CaCO3, irrespective of whether any or all of the calcium particles are of that form, comprise from 520 to 90% w/w of the granules,

the magnesium particles when expressed as magnesium oxide, irrespective of whether any or all of the magnesium particles are of that form, comprise at least 5% w/w of the granules and less than the % w/w of the calcium particles, and

the sodium particles when expressed as sodium chloride, irrespective of whether any or all of the sodium particles are of that form, comprise from 5 to 30% w/w of the granules;

and wherein the particles of each granule are of varied size within each particle type and/or between particle types;

and wherein each granule, to the extent it has a moisture content, it is at a moisture content less than that at which granulation has occurred such that most or all of the water or moisture used for aggregation has been dried away;

and wherein optionally each granule can include one or more other inclusions:

and wherein the granulation process includes the steps of:

- screening the granules produced by granulation of the consistent mix ratio of the at least three types of particle so as to obtain:
- (i) dietary supplement granules that are greater than 1 mm and less than 5 mm in size; and
- (ii) granules that are greater than 5 mm in size; and

(b) returning at least some of the material from the granules that are 18 921. Dietary supplement granules Granules of any one of claims greater than 5 mm in size to a granulator via a crusher and screening the material so as to obtain dietary supplement granules that are greater than 1 mm and less than 5 mm in size.

- 2.Granules of claim 1 less than 8mm in size.
- 3. Granules of claim 2 greater than 1mm in size.
- 24.Dietary supplement granules Granules of claim is 1, 2 or 3 5mm.
- 2 5. Dietary supplement granules Granules of claim 1 any-one-efthe-preeeding-elaims wherein the calcium particles are or include calcium carbonate.
- 3 6. Dietary supplement granules Granules of any one of claims 1 to 24 wherein the calcium particles are or include calcium sulphate.
- 47. <u>Dietary supplement granules</u> Granules of any one of the preceding claims wherein the calcium particles, when expressed as CaCO3, are in the range of up to 80% w/w of the granules.
- 5 8. Dietary supplement granules Granules of claim 74 wherein the calcium particles, when expressed as CaCO3, are at least 70% w/w of the granules.
- 6 9. Dietary supplement granules Granules of any one of claims 1 to 8-5 wherein the magnesium particles are or include magnesium
- 7 10. Dietary supplement granules Granules of any one of claims 1 to 8-5 wherein the magnesium particles are not or do not include magnesium oxide.
- 8 11. Dietary supplement granules Granules of any one of claims 1 to 710 wherein the magnesium particles are below 50% w/w of the granules.
- 9 12. Dietary supplement granules Granules of claim 811 wherein the magnesium particles are

below 40% w/w of the granules.

- 10 3. Dietary supplement granules Granules of claims 811 or 129 wherein the magnesium particles are below 30% w/w of the gran-
- 11 4. Dietary supplement granules Granules of claim 130 wherein the magnesium particles are below 20% w/w of the granules.
- 12 5. Dietary supplement granules Granules of any one of claims 1 to 411 wherein the granules comprise about 75:15:10 of the calcium particles, magnesium particles and sodium particles respective-
- 13 6. Dietary supplement granules Granules of any one of claims 1,2 or 4 to 11 to 4 wherein the granules comprise about 75:15:10 of CaCO3, the magnesium particles and NaCl respectively.
- 147. Dietary supplement granules Granules of any one of claims 1 to 114 of content ratio 75:15:10 when notionally expressed as CaCO3, MgO and NaCl.
- 158. Dietary supplement granules Granules of any one of claims 1 to 11 4-wherein the granules comprise about 75:10:15 of the calcium particles, magnesium particles and sodium particles respectively.
- 169. Dietary supplement granules Granules of any one of claims 1, 2, or 4 to 11 to 4 wherein the granules comprise about 75:10:15 of CaCO3, the magnesium particles and NaCl respectively.
- 17 20. Dietary supplement granules Granules of any one of claims 1 to 114 of content ratio of about 75:10:15 when notionally expressed as CaCO3, MgO and NaCl.
- 1 to 4 claim 1 being granules of a mix of at least

- (i) ground calcium carbonate sufficiently fine ground as to be nutritionally available.
- (ii) magnesium particles sufficiently fine ground as to be nutritionally available, and
- (iii) sodium chloride.
- 19 22. Dietary supplement granules Granules of claim I any one of claims 1 to 4 being granules of a mix of at least
- (i) calcium carbonate and calcium sulphate or calcium sulphate, all fine ground as to be nutritionally available,
- (ii) magnesium particles, fine ground as to be nutritionally available, and
- (iii) sodium chloride.
- 20 3. <u>Dietary supplement granules</u> Granules of any one of the preceding claims further comprising one or more other inclusions.
- 21 4. <u>Dietary supplement granules Granules</u> of claim <u>20</u>3 wherein the inclusions or inclusions are selected from any one or more of trace elements, vitamins, other salts of sodium, other salts of magnesium, rumen modifiers, monensin compositions, anthelmintics and animal remedies.
- 22 5. <u>Dietary supplement granules Granules</u> of any one of claims 1 to 212 further comprising a monensin compound.
- 23 6. <u>Dietary supplement granules Granules</u> of any one of the preceding claims wherein the granules have been granulated without a binder other than any that arises from their moistness at granulation and prior to dropping in moisture content.
- 24 7. <u>Dietary supplement granules</u> Granules of any one of the preceding claims wherein the granules were not granulated

with any cereal content.

25 8. <u>Dietary supplement granules</u> Granules of any one of the preceding claims wherein all of the calcium particles and

magnesium particles are sufficiently fine to be in a nutritionally available form.

26. Dietary supplement granules suitable for animals, each granule being a granulation of consistent mix ratio of at least three types of particle, the particles being

(i) particles of at least one particulate source of calcium not in the zero oxidation state and in a nutritionally available form ("calcium particles").

(ii) particles of at least one particulate source of magnesium not in the zero oxidation state and in a nutritionally available form ("magnesium particles"), and

(iii) particles of at least one particulate source of sodium not in the zero oxidation state and in a nutritionally available form ("sodium particles");

#### wherein

the calcium particles when expressed as CaCO3, irrespective of whether any or all of the calcium particles are of that form, comprise from 50 to 90% w/w of the granules,

the magnesium particles when expressed as magnesium oxide, irrespective of whether any or all of the magnesium particles are of that form, comprise at least 5% w/w of the granules and less than the % w/w of the calcium particles, and

the sodium particles when expressed as sodium chloride, irrespective of whether any or all of the sodium particles are of that form, comprise from 5 to 30% w/w of the granules;

and wherein the particles of each granule are of varied size within each particle type and/or between particle types;

and wherein each granule, to the extent it has a moisture content, it is at a moisture content less than that at which granulation has

occurred -such that most or all of the water or moisture used for aggregation has been dried away;

and wherein each granule includes a monensin compound as an inclusion;

and wherein the granulation process includes the steps of:
(a) screening the granules produced by granulation of the consistent mix ratio of the at least three types of particle so as to obtain:

(i) dietary supplement granules that are greater than 1 mm and less than 5 mm in size; and

(ii) granules that are greater than 5 mm in size; and

(b) returning at least some of the material from the granules that are greater than 5 mm in size to a granulator via a crusher and screening the material so as to obtain dietary supplement granules that are greater than 1 mm and less than 5 mm in size.

27. Dietary supplement granules suitable for animals, each granule being a granulation of consistent mix ratio of at least three types of particle, the particles being

(i) particles of at least one particulate source of calcium not in the zero oxidation state and in a nutritionally available form ("calcium particles"),

(ii) particles of at least one particulate source of magnesium not in the zero oxidation state and in a nutritionally available form ("magnesium particles"), and

(iii) particles of at least one particulate source of sodium not in the zero oxidation state and in a nutritionally available form ("sodium particles");

#### wherein

the calcium particles when expressed as CaCO3, irrespective of whether any or all of the calcium particles are of that form, comprise from 50 to 90% w/w of the granules,

the magnesium particles when expressed as magnesium oxide, irrespective of whether any or all of the magnesium particles are of that form, comprise at least 5% w/w of the granules and less than the % w/w of the calcium particles, and

the sodium particles when expressed as sodium chloride, irrespective of whether any or all of the sodium particles are of that form, comprise from 5 to 30% w/w of the granules;

and wherein the particles of each granule are of varied size within each particle type and/or between particle types;

and wherein each granule, to the extent it has a moisture content, it is at a moisture content less than that at which granulation has occurred such- that most or all of the water or moisture used for aggregation has been dried away;

and wherein each granule includes zinc as an inclusion, wherein the zinc when expressed as ZnO, irrespective of whether any or all of the zinc is of that form, comprises at least 0.6% w/w of the granules:

and wherein the granulation process includes the steps of:

(a) screening the granules produced by granulation of the consistent mix ratio of the at least three types of particle so as to obtain:

(i) dietary supplement granules that are greater than 1 mm and less than 5 mm in size: and

(ii) granules that are greater than 5 mm in size: and

(b) returning at least some of the material from the granules that are greater than 5 mm in size to a granulator via a crusher and screening the material so as to obtain dietary supplement granules that are greater than 1 mm and less than 5 mm in size.

28 9. Use of <u>dietary supplement granules granules</u>-of any one of the preeceeding claims in the manufacture of a formulation for supplementing the diet of an animal.

29\_30. A method of supplementing the diet of a non-human animal comprising providing to the animal dietary supplement granules granules of any one of claims 1 to 278.

30 1. <u>Dietary supplement granules Granules of any of claims 1 to 27</u> substantially as herein described with reference to any example thereof.

31 2. A use of claim 289 or method of claim 29 substantially as herein described with reference to any example thereof.

33. A method of claim 30 substantially as heroin described with reference to any example thereof.

IPONZ considers all such amendments address previous objections and that s85(3)(a) is considered to remain as met in this respect.

#### Full particulars of the reasons for amendments

The patentee notes in their letter of 10 November 2023 that the reasons for amendments are to disclaim subject matter that has been asserted in the revocation proceedings to anticipate or render obvious granted claim 1. The patentee notes that they have elected to pursue the claimed invention in three separate independent claims for the sake of clarity, rather than a single independent claim having alternative disclaimers.

The patentee notes in their letter of 10 November 2023:

"Thus, the subject matter of granted claim 1 has been divided into independent claims 1, 27, and 28. Those claims differ in the following ways:

Claim 1 requires the calcium particles (as defined) to comprise from 52-90% w/w of the granules, but places no limitation on the nature of the optional inclusion. When compared with granted claim 1, the lower limit of the numerical range defining the calcium particle content has been increased —which is clearly a disclaimer. The amendment of the lower limit is fairly based on page 8 (lines 8-12) of the specification which discloses that "reference to a range of numbers disclosed herein [such as 50-90] also incorporates reference to... any range of rational numbers within that range [such as 52-90]";

Claim 27 requires the calcium particles (as defined) to comprise from 50-90% w/w of the granules, and requires each granule to include monensin as an inclusion. When compared with granted claim 1, the granules must now contain a specific inclusion, rather than *any* inclusion being *merely* optional — which is clearly a disclaimer. The specific inclusion of monensin in the granules is fairly based on granted claim 25 and page 3 (line 16) of the specification; and

Claim 28 requires the calcium particles (as defined) to comprise from 50-90% w/w of the granules, and requires each granule to include zinc as an inclusion. When compared with accepted

claim 1, the granules must now contain a specific inclusion, rather than *any* inclusion being merely *optional—which* is clearly a disclaimer. The specific inclusion of zinc in the granules is fairly based on granted claim 24 and page 3 (line 15) of the specification.

Dependent claim 29 contains further details of an original feature covered by the pre-amended claims and is fairly based on page 7 (lines 3-4) of the specification. In line with the decision in *Sherman v Merck & Co Inc* IPO P46/2006 the introduction of such a dependent claim is allowable. In addition, or in the alternative, the insertion of dependent claim 29 is allowable since it further concretely defines (explanation) that the claimed method includes a drying step in which not only some of the water is removed, but most of the water used for granulation is removed.

A number of common disclaimers and/or explanations are applied to each of claims 1, 27, and 28:

the amendment to specify that the excess water has been removed is a disclaimer of those embodiments in which, for example, no water is removed, or only a *de minimus* amount of water is removed. The amendment thus also adds to the clarity of the claim language (explanation). The claim language is now more in line with the text on pages 3, 7, and 9 (line 28); the amendment to define the granulation process in more detail is clearly a disclaimer of the use of those granulation processes that would otherwise not, for example, produce granules of the size range specified. The claim language is now more in line with the text on page 7 (lines 3-4), page 9 (line 28), and in previous claims 2 and 3; and

the amendment to require that some granules that are greater than 8mm in size are returned to the granulator via a crusher to obtain the desired size is a further limitation and hence a disclaimer. The amendment finds fair basis on page 9 of the specification.

The amendment to the remaining dependent claims is made by way of disclaimer and/or correction to renumber the claims accordingly and to refer to the more appropriate language of "dietary supplement granules" rather than "granules"."

The patentee has referred in the above penultimate paragraph to "fair basis". However, IPONZ considers that all proposed amendments are also supported, as required by regulation 87.

Thus, IPONZ considers that for the latest proposed amendments 585(3)(a), s85(3)(b) remain met, that r87 has been met in full, and that all amendments now proposed are allowable prima facie.

Any person may, give notice to the Commissioner of opposition to a proposed amendment within 2 months after the date of the publication in Journal 1737 publication date 22 March 2024, as per s87(1) and r89(1).